COMMUNIQUÉS West-GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
16/10/2025
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will [...]
National PKU Alliance Grant Advances Engineered Native Bacteria Candidate for Phenylketonuria (PKU)
16/10/2025
San Diego, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Endure Biotherapeutics, Inc. (Endure Bio®), a pioneer in engineered engraftable microbial therapeutics, today announced that its founding discovery laboratory at the [...]
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
16/10/2025
Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a [...]
Cellectis organise aujourd’hui son R&D Day pour présenter les avancées de son portefeuille et ses perspectives à long terme
16/10/2025
L’ensemble des données de phase 1 et la stratégie de l’essai clinique pivot de phase 2 pour le produit candidat lasmé-cel (UCART22) dans la LAL-B en rechute ou réfractaire, seront présentées durant l’événement NEW YORK [...]
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
16/10/2025
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/10/2025
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025
16/10/2025
BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510 Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to re-potentiate [...]
Ligand to Host Investor Day on December 9, 2025
16/10/2025
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a [...]
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
16/10/2025
Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 [...]
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
16/10/2025
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today [...]
Omada Health to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
16/10/2025
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, [...]
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
16/10/2025
Will Showcase Latest Fertility Solutions SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more [...]
SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
16/10/2025
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant [...]
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
16/10/2025
First-time presentation examining bone outcomes in early postmenopausal women JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein [...]
Dr. James Chim to Receive Asian Myeloma Network Distinguished Service Award at the 9th AMN Summit in Nagoya
16/10/2025
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 9th AMN Summit in Nagoya, Japan on Saturday, October 18. NAGOYA, Japan, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation ( [...]
Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184
16/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Cannabix Technologies Delivers BreathLogix Alcohol Screening Device to Oilfield Transportation Services Company
16/10/2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is [...]
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
16/10/2025
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. ( [...]
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
16/10/2025
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc [...]

Pages